Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Equity (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Return on Equity for 6 consecutive years, with 0.58% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 15.0% to 0.58% in Q4 2025 year-over-year; TTM through Nov 2025 was 0.58%, a 15.0% decrease, with the full-year FY2025 number at 0.5%, up 4.0% from a year prior.
  • Return on Equity was 0.58% for Q4 2025 at Nurix Therapeutics, up from 0.6% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.26% in Q3 2021 to a low of 0.78% in Q1 2024.
  • A 5-year average of 0.5% and a median of 0.55% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -69bps in 2021, then surged 37bps in 2025.
  • Nurix Therapeutics' Return on Equity stood at 0.33% in 2021, then crashed by -71bps to 0.56% in 2022, then fell by -19bps to 0.66% in 2023, then soared by 35bps to 0.43% in 2024, then tumbled by -36bps to 0.58% in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Return on Equity are 0.58% (Q4 2025), 0.6% (Q3 2025), and 0.45% (Q2 2025).